Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of 177Lu-NYM032 in PSMA-positive metastatic castration-resistant prostate cancer
CTR20241097Phase 2Active
- Sponsor
- Norroy Bioscience
- Start
- May 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of NY108 in prostate cancer (PCa), sponsored by Norroy Bioscience. Started May 2024; status: active.
02
Drugs
NY108
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20241097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241097.